Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Silgard in Recurrent Respiratory Papillomatosis
NCT01375868Phase 3Completed
- Start
- Oct 2011
- Primary completion
- Dec 2018
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle in recurrent respiratory papillomatosis (RRP). Primary endpoint: Occurrence or frequency of recurrences of laryngeal papillomatosis at 5 years. Started Oct 2011; status: completed.
02
Drugs
quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle
03
Conditions
recurrent respiratory papillomatosis (RRP)
Beyond the preview
Go deeper on NCT01375868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01375868.